Q2 FY2026 EarningsQ2 FY26 revenue reached $21.7M, miss consensus of $28.7M by 24.4%, but grew 18% YoY. Despite the top-line miss relative to analyst models, GAAP EPS of -$0.25 significantly beat the expected -$0.41, driven by disciplined OPEX management (down 6% YoY) and strong gross margins of 81.9%. The company raised FY26 revenue guidance to $86M-$89M and anticipates reaching cash flow breakeven in Q4 FY26.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Avita Medical(RCEL) the Revenue is 21.25 M (+14.95%), Beat estimate;the EBIT is -6.714 M (+40.01%), Beat estimate;the EPS is -0.245 (+35.82%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.02B14.95%
0.02B6.95%
+0.00B8.00%
EBITExceed expectations
-0.01B40.01%
-0.01B29.53%
+0.00B10.48%
EPSExceed expectations
-0.244935.82%
-0.285825.09%
+0.040910.73%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf